

Contacts:

Kara Fitzsimmons +1 212 504 6708

kara.fitzsimmons@cwt.com

Robert Robertson +1 212 504 6897

robert.robertson@cwt.com

NewsRelease

For Immediate Release:

Cadwalader Represents The Medicines Company in its Private Offering of \$402,500,000 Convertible Senior Notes Due 2023

New York, NY, June 16, 2016 - Cadwalader represented The Medicines Company (NASDAQ: MDCO), a provider of solutions in serious infectious disease care, acute cardiovascular care and surgery and perioperative care, in its private offering of \$402,500,000 convertible Senior Notes due 2023.

The aggregate principal amount of notes sold reflects the exercise in full by the initial purchasers of the Notes of their option to purchase up to an additional \$52.5 million in aggregate principal amount of Notes. The Medicines Company estimates that the net proceeds from the offering will be approximately \$390.8 million. The Notes will bear cash interest at a rate of 2.75% per year, payable semi-annually on January 15 and July 15 of each year, beginning on January 15, 2017. The Notes will mature on July 15, 2023. The Medicines Company intends to use the proceeds of the offering to repurchase certain of its existing convertible Senior Notes in privately negotiated transactions.

Cadwalader also advised The Medicines Company on related capped call transactions entered into in connection with the convertible Senior Notes offering.

The New York based Cadwalader team was led by corporate partner Gregory Patti, special counsel Adam Summers, senior attorney Daniel Zimmerman, and, associates Alexandra Cotter and Saadia Ghazi and financial services partner Ray Shirazi and associate Nick Allen.

About Cadwalader, Wickersham & Taft LLP

Cadwalader, Wickersham & Taft LLP, established in 1792, serves a diverse client base, including many of the world's leading financial institutions and corporations in more than 50

countries. With offices in New York, London, Charlotte, Washington, Houston, Beijing, Hong Kong and Brussels, Cadwalader offers legal expertise in antitrust, banking, corporate finance, corporate governance, energy, environmental, executive compensation, financial restructuring, health care, intellectual property, litigation, mergers and acquisitions, private equity, private wealth, real estate, regulation, securitization, structured finance, tax and white collar defense. For more information, visit www.cadwalader.com.

About The Medicines Company

The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on the leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: serious infectious disease care, acute cardiovascular care and surgery and perioperative care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers in Parsippany, NJ, USA and Zurich, Switzerland. www.themedicinescompany.com.